Crizotinib 2025 medical insurance reimbursement policy

Crizotinib is a tyrosine kinase inhibitor (TKI) targeting the rearrangement or amplification of ALK, ROS1 and MET genes. It is mainly used for the treatment of specific gene-positive advanced non-small cell lung cancer (NSCLC). Clinically, its indications include: first-line treatment of ALK-positive advanced or metastatic NSCLC; use in patients with ROS1-positive NSCLC; and some NSCLC patients with MET exon 14 skipping mutations. These genetic changes lead to abnormal activation of tumor cell signaling pathways, thereby driving the growth and spread of cancer cells. Crizotinib effectively inhibits tumor progression by blocking related signaling.

In China, crizotinib has been launched in the form of "XALKORI" capsules, with specifications of 250 mg 60 capsules and 200 mg 60 capsules. The retail price of each box is often more than 10,000 yuan. However, the implementation of the national medical insurance policy has greatly reduced the financial burden on patients. Since it entered the national medical insurance directory, patients who meet the positive test results of ALK or ROS1 and meet the treatment indications can be reimbursed according to the medical insurance proportion, and the actual out-of-pocket expenses have dropped significantly. The reimbursement ratio of medical insurance varies slightly in different regions, generally around 70%. At the same time, critical illness insurance or local supplementary medical security can also be added to further reduce financial pressure.

Medical insurance access is of great significance to the popularization of targeted drugs. It not only improves clinical accessibility, but also promotes the popularization of molecular testing, allowing more patients to benefit from precise treatments. In some areas with limited economic conditions, medical insurance reimbursement is an important guarantee for standardized treatment of patients. As competition among domestic molecularly targeted drugs intensifies and generic drugs are launched, the price of crizotinib is expected to fall further in the future, thereby benefiting more lung cancer patients.

Overall, crizotinib’s dual advantages in indication coverage and medical insurance support enable it to occupy an important position in the precision treatment of advanced NSCLC in China.

Reference materials:https://go.drugbank.com/drugs/DB08865